Fluidigm Seeks to Retain Lead in Burgeoning dPCR Market with Higher-Density Chip Offerings

The company is developing versions of its Digital Array PCR chips that will enable "hundreds of thousands" of PCR reactions to be performed in parallel; and is working with academic collaborators to push its technology into the realm of "millions of dPCR reactions per chip," an executive said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.